替奈普酶静脉溶栓后桥接取栓治疗卒中
BRIDGE-TNK为在中国进行的开放标签随机试验,纳入大血管闭塞急性缺血性卒中发病4.5小时内且符合溶栓条件的患者,随机接受替奈普酶静脉溶栓后桥接取栓或单纯取栓。主要终点90天功能独立(改良Rankin量表0–2分)在桥接组为52.9%,单纯取栓组为44.1%(未校正风险比1.20;95%CI 1.01–1.43;P=0.04)。取栓前成功再灌注桥接组6.1%、单纯取栓组1.1%,取栓后成功再灌注分别为91.4%和94.1%。48小时内症状性颅内出血分别为8.5%和6.7%,90天死亡分别为22.3%和19.9%。
要点
- 大血管闭塞急性缺血性卒中发病4.5小时内符合溶栓条件者,替奈普酶桥接取栓组90天功能独立52.9%,单纯取栓组44.1%(未校正风险比1.20;95%CI 1.01–1.43;P=0.04)。
- 取栓前成功再灌注桥接组6.1%、单纯取栓组1.1%;取栓后成功再灌注桥接组91.4%、单纯取栓组94.1%。
- 48小时内症状性颅内出血桥接组8.5%、单纯取栓组6.7%;90天死亡桥接组22.3%、单纯取栓组19.9%。
- 该试验为开放标签设计,纳入中国发病4.5小时内且符合溶栓条件的大血管闭塞患者,随机分配至替奈普酶桥接取栓组278例或单纯取栓组272例。
适用人群与场景
- 中国急性缺血性卒中因大血管闭塞、发病4.5小时内、符合溶栓条件的患者。
研究设计与关键结果
- 开放标签随机试验,替奈普酶桥接取栓组278例,单纯取栓组272例。
- 主要终点90天功能独立(改良Rankin量表0–2分):桥接组147例(52.9%)vs 单纯取栓组120例(44.1%),未校正风险比1.20(95%CI 1.01–1.43;P=0.04)。
- 取栓前成功再灌注:桥接组6.1% vs 单纯取栓组1.1%;取栓后成功再灌注:桥接组91.4% vs 单纯取栓组94.1%。
- 48小时内症状性颅内出血:桥接组8.5% vs 单纯取栓组6.7%;90天死亡:桥接组22.3% vs 单纯取栓组19.9%。
证据类型、等级与局限
- 证据类型:开放标签随机试验(BRIDGE-TNK,ClinicalTrials.gov NCT04733742)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于大血管闭塞急性缺血性卒中发病4.5小时内且符合溶栓条件的患者,作者结论认为替奈普酶静脉溶栓后桥接取栓较单纯取栓提高90天功能独立比例。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The safety and efficacy of treatment with intravenous tenecteplase before endovascular thrombectomy in patients with acute ischemic stroke due to large-vessel occlusion remain uncertain.
METHODS: In this open-label trial conducted in China, we randomly assigned patients with acute ischemic stroke due to large-vessel occlusion who had presented within 4.5 hours after onset and were eligible for thrombolysis to receive either intravenous tenecteplase followed by endovascular thrombectomy or endovascular thrombectomy alone. The primary outcome was functional independence (a score of 0 to 2 on the modified Rankin scale; range, 0 to 6, with higher scores indicating more severe disability) at 90 days. Secondary outcomes included successful reperfusion before and after thrombectomy. Safety outcomes included symptomatic intracranial hemorrhage within 48 hours and death within 90 days.
RESULTS: A total of 278 patients were randomly assigned to the tenecteplase-thrombectomy group and 272 to the thrombectomy-alone group. Functional independence at 90 days was observed in 147 patients (52.9%) in the tenecteplase-thrombectomy group and in 120 patients (44.1%) in the thrombectomy-alone group (unadjusted risk ratio, 1.20; 95% confidence interval, 1.01 to 1.43; P = 0.04). A total of 6.1% of the patients in the tenecteplase-thrombectomy group and 1.1% of those in the thrombectomy-alone group had successful reperfusion before thrombectomy, and 91.4% and 94.1%, respectively, had successful reperfusion after thrombectomy. Symptomatic intracranial hemorrhage within 48 hours occurred in 8.5% of the patients in the tenecteplase-thrombectomy group and in 6.7% of those in the thrombectomy-alone group; mortality at 90 days was 22.3% and 19.9%, respectively.
CONCLUSIONS: Among patients with acute ischemic stroke due to large-vessel occlusion who had presented within 4.5 hours after onset, the percentage of patients with functional independence at 90 days was higher with intravenous tenecteplase plus endovascular thrombectomy than with endovascular thrombectomy alone. (Funded by the Chongqing Science and Health Joint Medical Research Project and others; BRIDGE-TNK ClinicalTrials.gov number, NCT04733742.).
参考来源
- Qiu Z, Li F, Sang H, et al. Intravenous Tenecteplase before Thrombectomy in Stroke. N Engl J Med. 2025. PMID: 40396577. doi:10.1056/NEJMoa2503867
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。